First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+metastatic breast cancer (MBC).

被引：36
|
作者：
Alsina, Maria
Boni, Valentina
Schellens, Jan H. M.
Moreno, Victor
Bol, Kees
Westendorp, Martine
Sirulnik, L. Andres
Tabernero, Josep
Calvo, Emiliano
机构：
[1] Vall Hebron Univ Hosp, Barcelona, Spain
[2] START Madrid CIOCC, Hosp HM Univ Sanchinarro, Madrid, Spain
[3] Netherlands Canc Inst, Amsterdam, Netherlands
[4] Start Madrid FJD, Hosp Fdn, Madrid, Spain
[5] Merus NV, Utrecht, Netherlands
[6] Vall Hebron Univ Hosp, Inst Oncol VHIO, Barcelona, Spain
[7] START Madrid, Centro Integral Oncol Clara Campal, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.2522
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2522
引用
收藏
页数：6
相关论文
共 50 条
  • [41] Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer
    Pegram, M.
    Hamilton, E.
    Tan, A. R.
    Storniolo, A. M.
    Elgeioushi, N.
    Marshall, S.
    Abdullah, S.
    Patel, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer
    Yuan, Yuan
    Lee, Jin Sun
    Yost, Susan E.
    Stiller, Tracey
    Blanchard, M. Suzette
    Padam, Simran
    Katheria, Vani
    Kim, Heeyoung
    Sun, Canlan
    Tang, Aileen
    Martinez, Norma
    Patel, Niki Dipesh
    Sedrak, Mina S.
    Waisman, James
    Li, Daneng
    Sanani, Shamel
    Presant, Cary A.
    Mortimer, Joanne
    JOURNAL OF GERIATRIC ONCOLOGY, 2021, 12 (05) : 752 - 758
  • [43] First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast cancer: Results from a phase I study
    Zhang, Jian
    Ji, Dongmei
    Cai, Li
    Yao, Herui
    Yan, Min
    Wang, Xiaojia
    Shen, Weina
    Du, Yiqun
    Pang, Hui
    Lai, Xiuping
    Zeng, Huiai
    Huang, Jian
    Sun, Yan
    Peng, Xinxin
    Xu, Junfang
    Yang, Jing
    Yang, Fei
    Xu, Ting
    Hu, Xichun
    CANCER RESEARCH, 2022, 82 (04)
  • [44] First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
    Zhang, Jian
    Ji, Dongmei
    Cai, Li
    Yao, Herui
    Yan, Min
    Wang, Xiaojia
    Shen, Weina
    Du, Yiqun
    Pang, Hui
    Lai, Xiuping
    Zeng, Huiai
    Huang, Jian
    Sun, Yan
    Peng, Xinxin
    Xu, Junfang
    Yang, Jing
    Yang, Fei
    Xu, Ting
    Hu, Xichun
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 618 - 628
  • [45] A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (BC)
    Beeram, M.
    Krop, I.
    Modi, S.
    Tolcher, A.
    Rabbee, N.
    Girish, S.
    Tibbitts, J.
    Holden, S.
    Lutzker, S.
    Burris, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors.
    Richards, Donald A.
    Braiteh, Fadi S.
    Garcia, A. A.
    Denlinger, Crystal Shereen
    Conkling, Paul R.
    Edenfield, William Jeffery
    Anthony, Stephen Patrick
    Hellerstedt, Beth A.
    Raju, Robert N.
    Becerra, Carlos
    Harb, Wael A.
    Smith, David A.
    McDonagh, Charlotte Fenton
    Kawash, Kate-Lyn
    Frye, Sasha
    Moyo, Victor M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] A phase 1b study of ONT 380, an oral HER2-specific inhibitor, combined with ado trastuzumab emtansine (T DM1), in HER2+metastatic breast cancer (MBC)
    Ferrario, C.
    Hamilton, E.
    Aucoin, N.
    Falkson, C. L.
    Khan, Q.
    Krop, I. E.
    Welch, S.
    Bedard, P. L.
    Conlin, A.
    Chaves, J.
    Vo, A.
    Walker, L.
    Borges, V.
    CANCER RESEARCH, 2016, 76
  • [48] A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with adotrastuzumab emtansine (T-DM1), in HER2+metastatic breast cancer (MBC)
    Borges, Virginia F.
    Hamilton, Erika Paige
    Yardley, Denise A.
    Moulder, Stacy L.
    Hortobagyi, Gabriel N.
    Walker, Luke N.
    Krop, Ian E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination
    Balz, Lydia M.
    Bartkowiak, Kai
    Andreas, Antje
    Pantel, Klaus
    Niggemann, Bernd
    Zaenker, Kurt S.
    Brandt, Burkhard H.
    Dittmar, Thomas
    JOURNAL OF PATHOLOGY, 2012, 227 (02): : 234 - 244
  • [50] A phase 1 study of ARX788, a HER2-targeting antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer
    Hu, Xichun
    Zhang, Jian
    Ji, Dongmei
    Xia, Gang
    Ji, Yanping
    Xiong, Gaozhun
    Liang, Xuejun
    CANCER RESEARCH, 2020, 80 (04)
12345